Contact

All Stories

  1. Autism genes and the leukocyte transcriptome in autistic toddlers relate to pathogen interactomes, infection and the immune system. A role for excess neurotrophic sAPPα and reduced antimicrobial Aβ

    Article • Neurochemistry International, June 2019, Elsevier

    Dr Christopher Carter

  2. The Porphyromonas gingivalis/Host Interactome Shows Enrichment in GWASdb Genes Related to Alzheimer's Disease, Diabetes and Cardiovascular Diseases

    Article • Frontiers in Aging Neuroscience, December 2017, Frontiers

    Dr Christopher Carter

  3. Genetic, Transcriptome, Proteomic, and Epidemiological Evidence for Blood-Brain Barrier Disruption and Polymicrobial Brain Invasion as Determinant Factors in Alzheimer’s Disease

    Article • Journal of Alzheimer s Disease Reports, September 2017, IOS Press

    Dr Christopher Carter

  4. Autism genes are selectively targeted by environmental pollutants including pesticides, heavy metals, bisphenol A, phthalates and many others in food, cosmetics or household products

    Article • Neurochemistry International, December 2016, Elsevier

    Dr Christopher Carter

  5. The barrier, airway particle clearance, placental and detoxification functions of autism susceptibility genes

    Article • Neurochemistry International, October 2016, Elsevier

    Dr Christopher Carter

  6. Microbes and Alzheimer’s Disease

    Article • Journal of Alzheimer s Disease, April 2016, IOS Press

    Professor George Perry, Professor Douglas B Kell, Dr Christopher Carter, Ruth Itzhaki

  7. Susceptibility genes are enriched in those of the herpes simplex virus 1/host interactome in psychiatric and neurological disorders

    Article • Pathogens and Disease, September 2013, Oxford University Press (OUP)

    Dr Christopher Carter

  8. Toxoplasmosis and Polygenic Disease Susceptibility Genes: ExtensiveToxoplasma gondiiHost/Pathogen Interactome Enrichment in Nine Psychiatric or Neurological Disorders

    Article • Journal of Pathogens, January 2013, Hindawi Publishing Corporation

    Dr Christopher Carter

  9. Vaccinia and other viruses with available vaccines show marked homology with the HIV-1 envelope glycoprotein: The prospect of using existing vaccines to stem the AIDS pandemic

    Article • Immunopharmacology and Immunotoxicology, August 2011, Taylor & Francis

    Dr Christopher Carter

  10. Extensive viral mimicry of 22 AIDS-related autoantigens by HIV-1 proteins and pathway analysis of 561 viral/human homologues suggest an initial treatable autoimmune component of AIDS

    Article • FEMS Immunology & Medical Microbiology, August 2011, Oxford University Press (OUP)

    Dr Christopher Carter

  11. Pathogen and autoantigen homologous regions within the cystic fibrosis transmembrane conductance regulator (CFTR) protein suggest an autoimmune treatable component of cystic fibrosis

    Article • FEMS Immunology & Medical Microbiology, July 2011, Oxford University Press (OUP)

    Dr Christopher Carter

  12. Epstein–Barr and other viral mimicry of autoantigens, myelin and vitamin D-related proteins and of EIF2B, the cause of vanishing white matter disease: massive mimicry of multiple sclerosis relevant proteins by theSynechococcusphage

    Article • Immunopharmacology and Immunotoxicology, April 2011, Taylor & Francis

    Dr Christopher Carter

  13. Alzheimer's disease plaques and tangles: Cemeteries of a Pyrrhic victory of the immune defence network against herpes simplex infection at the expense of complement and inflammation-mediated neuronal destruction

    Article • Neurochemistry International, February 2011, Elsevier

    Dr Christopher Carter

  14. Alzheimer's Disease: APP, Gamma Secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and Their Relationships with Herpes Simplex,C. Pneumoniae, Other Suspect Pathogens, and the Immune System

    Article • International Journal of Alzheimer s Disease, January 2011, Hindawi Publishing Corporation

    Dr Christopher Carter

  15. Schizophrenia: A Pathogenetic Autoimmune Disease Caused by Viruses and Pathogens and Dependent on Genes

    Article • Journal of Pathogens, January 2011, Hindawi Publishing Corporation

    Dr Christopher Carter

  16. The Fox and the Rabbits—Environmental Variables and Population Genetics (1) Replication Problems in Association Studies and the Untapped Power of GWAS (2) Vitamin A Deficiency, Herpes Simplex Reactivation and Other Causes of Alzheimer's Disease

    Article • ISRN Neurology, January 2011, Hindawi Publishing Corporation

    Dr Christopher Carter

  17. APP, APOE, complement receptor 1, clusterin and PICALM and their involvement in the herpes simplex life cycle

    Article • Neuroscience Letters, October 2010, Elsevier

    Dr Christopher Carter

  18. Alzheimer's Disease: A Pathogenetic Autoimmune Disorder Caused by Herpes Simplex in a Gene-Dependent Manner

    Article • International Journal of Alzheimer s Disease, January 2010, Hindawi Publishing Corporation

    Dr Christopher Carter

  19. Schizophrenia Susceptibility Genes Directly Implicated in the Life Cycles of Pathogens: Cytomegalovirus, Influenza, Herpes simplex, Rubella, and Toxoplasma gondii

    Article • Schizophrenia Bulletin, June 2008, Oxford University Press (OUP)

    Dr Christopher Carter

  20. Interactions between the products of the Herpes simplex genome and Alzheimer's disease susceptibility genes: Relevance to pathological-signalling cascades

    Article • Neurochemistry International, May 2008, Elsevier

    Dr Christopher Carter

  21. Multiple genes and factors associated with bipolar disorder converge on growth factor and stress activated kinase pathways controlling translation initiation: Implications for oligodendrocyte viability

    Article • Neurochemistry International, February 2007, Elsevier

    Dr Christopher Carter

  22. Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis

    Article • Neurochemistry International, January 2007, Elsevier

    Dr Christopher Carter

  23. EIF2B and Oligodendrocyte Survival: Where Nature and Nurture Meet in Bipolar Disorder and Schizophrenia?

    Article • Schizophrenia Bulletin, October 2006, Oxford University Press (OUP)

    Dr Christopher Carter

  24. Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability

    Article • Schizophrenia Research, September 2006, Elsevier

    Dr Christopher Carter

  25. SL25.1131 [3(S),3a(S)-3-Methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a New, Reversible, and Mixed Inhibitor of Monoamine Oxidase-A and Monoamine Oxidase-B: Biochemical and Behavioral Profile

    Article • Journal of Pharmacology and Experimental Therapeutics, June 2004, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Christopher Carter

  26. Sequence Identification and Characterization of Human Carnosinase and a Closely Related Non-specific Dipeptidase

    Article • Journal of Biological Chemistry, December 2002, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Christopher Carter

  27. The pharmacology of native N-methtl-D-aspartate receptor subtypes: Different receptors control the release of different striatal and spinal transmitters

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, January 1998, Elsevier

    Dr Christopher Carter

  28. Inhibition of synaptosomal veratridine-induced sodium influx by antidepressants and neuroleptics used in chronic pain

    Article • Neuroscience Letters, December 1996, Elsevier

    Dr Christopher Carter

  29. Evidence for native NMDA receptor subtype pharmacology as revealed by differential effects on the NMDA-evoked release of striatal neuromodulators: Eliprodil, ifenprodil and other native NMDA receptor subtype selective compounds

    Article • Neurochemistry International, November 1996, Elsevier

    Dr Christopher Carter

  30. Pharmacology of N-methyl-d-aspartate-evoked [3H]noradrenaline release in adult rat spinal cord

    Article • European Journal of Pharmacology, July 1996, Elsevier

    Dr Christopher Carter

  31. Striatal NMDA receptor subtypes: the pharmacology of N-methyl-d-aspartate-evoked dopamine, γ-aminobutyric acid, acetylcholine and spermidine release

    Article • European Journal of Pharmacology, November 1995, Elsevier

    Dr Christopher Carter

  32. Release of spermidine from the rat cortex following permanent middle cerebral artery occlusion

    Article • Fundamental and Clinical Pharmacology, March 1995, Wiley

    Dr Christopher Carter

  33. Synergism between the NMDA receptor antagonistic effects of ifenprodil and the glycine antagonist, 7-chlorokynurenate, in vivo

    Article • European Journal of Pharmacology, April 1994, Elsevier

    Dr Christopher Carter

  34. Ornithine decarboxylase inhibition or NMDA receptor antagonism reduce cortical polyamine efflux associated with dialysis probe implantation

    Article • Neuroscience Letters, January 1993, Elsevier

    Dr Christopher Carter

  35. Neurotoxic effects of the intrastriatal injection of spermine and spermidine: lack of involvement of NMDA receptors

    Article • Brain Research, November 1992, Elsevier

    Dr Christopher Carter

  36. Selective Release of Spermine and Spermidine from the Rat Striatum by N-Methyl-d-Aspartate Receptor Activation In Vivo

    Article • Journal of Neurochemistry, June 1992, Wiley

    Dr Christopher Carter

  37. Difluoromethyl ornithine protects against the neurotoxic effects of intrastriatally administered N-methyl-D-aspartate in vivo

    Article • European Journal of Pharmacology, June 1991, Elsevier

    Dr Christopher Carter

  38. The effects ofN-methyl-d-aspartate and kainate lesions of the rat striatum on striatal ornithine decar☐ylase activity and polyamine levels

    Article • Brain Research, May 1991, Elsevier

    Dr Christopher Carter

  39. Ifenprodil and SL 82.0715 are antagonists at the polyamine site of the N-methyl-D-aspartate (NMDA) receptor

    Article • European Journal of Pharmacology, May 1989, Elsevier

    Dr Christopher Carter

  40. Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease

    Article • Journal of Neurochemistry, February 1989, Wiley

    Dr Christopher Carter

  41. Sodium dependence of NMDA's effects on cyclic GMP production in immature rat cerebellar slices

    Article • Neuroscience Letters, November 1988, Elsevier

    Dr Christopher Carter

  42. Noradrenaline Antagonizes and Ouabain Potentiates the Effects of iV-Methyl-D-Aspartate on Rat Cerebellar Cyclic GMP Production

    Article • Journal of Neurochemistry, September 1988, Wiley

    Dr Christopher Carter

  43. Differential Control by N-Methyl-D-Aspartate and Kainate of Striatal Dopamine Release In Vivo: A Trans-Striatal Dialysis Study

    Article • Journal of Neurochemistry, August 1988, Wiley

    Dr Christopher Carter

  44. Differential modulation of [3H]TCP binding to the NMDA receptor by L-glutamate and glycine

    Article • European Journal of Pharmacology, April 1988, Elsevier

    Dr Christopher Carter

  45. Raised extracellular potassium relieves the blockade by magnesium of NMDA-induced cerebellar cyclic GMP production

    Article • Neuroscience Letters, November 1987, Elsevier

    Dr Christopher Carter

  46. Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage

    Article • Brain Research, September 1987, Elsevier

    Dr Christopher Carter

  47. Ionic Mechanisms Implicated in the Stimulation of Cerebellar Cyclic GMP Levels by N-Methyl-D-Aspartate

    Article • Journal of Neurochemistry, July 1987, Wiley

    Dr Christopher Carter

  48. 2-Oxo-[14C]glutarate is taken up by glutamatergic nerve terminals in the rat striatum

    Article • Neuroscience Letters, December 1986, Elsevier

    Dr Christopher Carter

  49. Increased alanine aminotransferase activity in the Huntington's disease putamen

    Article • Journal of the Neurological Sciences, October 1984, Elsevier

    Dr Christopher Carter

  50. Reduced GABA transaminase activity in the Huntington's disease putamen

    Article • Neuroscience Letters, August 1984, Elsevier

    Dr Christopher Carter

  51. Glutamine synthetase and fructose-1, 6-diphosphatase activity in the putamen of control and Huntington's disease brain post mortem

    Article • Life Sciences, April 1983, Elsevier

    Dr Christopher Carter

  52. Glutamine synthetase activity in Huntington's disease

    Article • Life Sciences, September 1982, Elsevier

    Dr Christopher Carter

  53. Topographical distribution of possible glutamatergic pathways from the frontal cortex to the striatum and substantia nigra in rats

    Article • Neuropharmacology, May 1982, Elsevier

    Dr Christopher Carter

  54. GLUTAMINE, GLUTAMINE SYNTHETASE AND HUNTINGTON'S DISEASE

    Article • The Lancet, June 1981, Elsevier

    Dr Christopher Carter

  55. LOSS OF GLUTAMINE SYNTHETASE ACTIVITY IN THE BRAIN IN HUNTINGTON'S DISEASE

    Article • The Lancet, April 1981, Elsevier

    Dr Christopher Carter

  56. The role of 5-hydroxytryptamine in dopamine-dependent stereotyped behaviour

    Article • Neuropharmacology, March 1981, Elsevier

    Dr Christopher Carter

  57. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats

    Article • Nature, July 1980, Nature

    Dr Christopher Carter

  58. 5,7-dihydroxytryptamine lesions of the amygdala reduce amphetamine-and apomorphine-induced stereotyped behaviour in the rat

    Article • Naunyn-Schmiedeberg s Archives of Pharmacology, July 1980, Springer Science + Business Media

    Dr Christopher Carter

  59. Behavioural and biochemical effects of dopamine and noradrenaline depletion within the medial prefrontal cortex of the rat

    Article • Brain Research, June 1980, Elsevier

    Dr Christopher Carter

  60. Effect of 6-Hydroxydopamine Lesions of the Medial Prefrontal Cortex on Neurotransmitter Systems in Subcortical Sites in the Rat

    Article • Journal of Neurochemistry, January 1980, Wiley

    Dr Christopher Carter

  61. A comparison of l- and d-baclofen on dopamine dependent behaviour in the rat

    Article • Neuropharmacology, September 1979, Elsevier

    Dr Christopher Carter

  62. Potentiation of haloperidol-induced catalepsy by dopamine agonists: Possible involvement of central 5-hydroxytryptamine

    Article • Pharmacology Biochemistry and Behavior, April 1979, Elsevier

    Dr Christopher Carter

  63. The effects of 5,7-dihydroxytryptamine lesions of extrapyramidal and mesolimbic sites on spontaneous motor behaviour, and amphetamine-induced stereotypy

    Article • Naunyn-Schmiedeberg s Archives of Pharmacology, January 1979, Springer Science + Business Media

    Dr Christopher Carter

  64. A study of the sites of interaction between dopamine and 5-hydroxytryptamine for the production of fluphenazine-induced catalepsy

    Article • Naunyn-Schmiedeberg s Archives of Pharmacology, September 1978, Springer Science + Business Media

    Dr Christopher Carter

  65. Differential effects of central serotonin manipulation on hyperactive and stereotyped behaviour

    Article • Life Sciences, September 1978, Elsevier

    Dr Christopher Carter